LexDanaLexDanabeta
Inventor

Changgeng Qian

Inventor
Wayland, MA, US

Overview

48→
Patents
1997–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 48 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds34%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
A61KPreparations for medical, dental or toiletry purposes22%
Y02ATechnologies for adaptation to climate change8%
C07CAcyclic or carbocyclic compounds2%
G01CMeasuring distances, levels or bearings2%
G01SRadio direction-finding1%
G06VImage or video recognition or understanding1%
G08GTraffic control systems1%
PatentTitleYear
11,116,7673,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications202111,009,365Lane marking localization202111,009,356Lane marking localization and fusion202110,844,056Fused amino pyridine as HSP90 inhibitors202010,676,482Phosphoinositide 3-kinase inhibitors with a zinc binding moiety202010,543,197Phosphoinositide 3-kinase inhibitor with a zinc binding moiety202010,428,068Fused amino pyridine as HSP90 inhibitors201910,214,514Hedgehog antagonists having zinc binding moieties201910,183,941Pyrimidine or pyridopyridone compound and application thereof201910,035,797Fused amino pyridine as HSP90 inhibitors20189,725,461'Phosphoinositide 3-kinase inhibitors with a zinc binding moiety'20179,708,299'Hedgehog antagonists having zinc binding moieties'20179,630,965'Fused amino pyridine as HSP90 inhibitors'20179,402,832'Fused amino pyridine as HSP90 inhibitors'20169,249,156'Phosphoinositide 3-kinase inhibitor with a zinc binding moiety'20169,169,244'Tyrosine kinase inhibitors containing a zinc binding moiety'20159,108,929'Quinazoline based EGFR inhibitors'20159,040,556'Fused amino pyridine as HSP90 inhibitors'20159,024,024'Quinazoline based EGFR inhibitors containing a zinc binding moiety'20158,975,401'Quinazoline based EGFR inhibitors containing a zinc binding moiety'20158,906,909'Phosphoinositide 3-kinase inhibitors with a zinc binding moiety'20148,846,912'Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety'20148,722,703'Fused amino pyridines for the treatment of brain tumors'20148,710,219'Phosphoinositide 3-kinase inhibitor with a zinc binding moiety'20148,691,820'CDK inhibitors'20148,604,044'Quinazoline based EGFR inhibitors containing a zinc binding moiety'20138,586,605'Fused amino pyridine as HSP90 inhibitors'20138,563,741'CDK inhibitors containing a zinc binding moiety'20138,518,910'Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety'20138,461,157'Phosphoinositide 3-kinase inhibitors with a zinc binding moiety'20138,455,506'Quinazoline based EGFR inhibitors containing a zinc binding moiety'20138,426,419'Tyrosine kinase inhibitors containing a zinc binding moiety'20138,367,663'Phosphoinositide 3-kinase inhibitors with a zinc binding moiety'20138,349,856'Quinazoline based EGFR inhibitors'20138,324,240'Fused amino pyridine as HSP90 inhibitors'20128,273,785'Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety'20128,119,616'Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety'20127,977,347'Quinazoline based EGFR inhibitors'20117,928,136'Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety'20117,888,361'Tyrosine kinase inhibitors containing a zinc binding moiety'20117,846,938'Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety'20107,547,781'Quinazoline based EGFR inhibitors containing a zinc binding moiety'20096,569,895'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'20036,177,451'Epibatidine and derivatives thereof as nicotine cholinergic receptor agonists'20016,077,846'Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists'20006,025,384'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'20005,750,565'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'19985,703,093'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'1997

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1997–2021Based in Wayland, MA, US· patent location history
2009–2020Patents assigned to CURIS INC (38)· patent assignee history
2012–2014Patents assigned to CAI XIONG (15)· patent assignee history
2012–2014Patents assigned to QIAN CHANGGENG (15)· patent assignee history
2012–2014Patents assigned to ZHAI HAIXIAO (11)· patent assignee history
2012–2013Patents assigned to GOULD STEPHEN (4)· patent assignee history
2019Based in Guangdong, CN· patent location history
2021Based in San Diego, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
CURIS INC382009–2020
CAI XIONG152012–2014
QIAN CHANGGENGself152012–2014
ZHAI HAIXIAO112012–2014
GOULD STEPHEN42012–2013
Locations
LocationPatentsSpan
Wayland, Massachusetts, US451997–2021
San Diego, California, US22021
Guangdong, CN12019